CD274 and neoplasm: Preclinical studies demonstrate that co-administration of BRAF V600E inhibitors with anti-PD-1/PD-L1 antibodies significantly suppresses ATC progression and remodels the tumor immune microenvironment toward an immunologically active state [81,82].